- The FDA has authorized third vaccine with Johnson & Johnson one-shot jab to be distributed as early as Monday
- By the end of March, J&J has said it expects to deliver 20 million doses to the U.S., and 100 million by summer
- Worldwide, company aims to produce 1 billion doses globally by the end of 2021
- Johnson & Johnson shot only requires a single shot compared to Pfizer and Moderna’s jabs
VARIOUS MEDIA REPORTING..
The vaccine, made by Janssen, J&J’s vaccine arm, is safe and effective, and it’s considered flexible. It’s a single dose, and it doesn’t require special storage.
The vaccine is authorized for people ages 18 and older.
New Jersey-based Johnson & Johnson said 20 million doses would be delivered in the US by the end of March. The company plans to deliver 100 million doses during the first half of 2021.
The doses can be stored in a standard fridge, unlike the ultra-cold conditions required by the other two vaccines from Moderna and Pfizer/BioNTech, both of which are two-shot regimes.
“We need a vaccine that can be quickly mass produced,” Dr. Greg Poland, head of the Mayo Clinic’s Vaccine Research Group, said Friday. “We’d want to see a reasonable duration of efficacy and protection.